ASCO: Pemetrexed Plus Carboplatin No Better Than Bevacizumab-Containing Regimen in NSCLC
A phase III study, presented at ASCO, comparing pemetrexed and carboplatin with paclitaxel, carboplatin, and bevacizumab failed to find a difference in a composite endpoint of progression-free survival and severe drug-related toxicities in patients with nonsquamous non–small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news
Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - May 8, 2013 Category: Cancer & Oncology Source Type: news
Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - May 8, 2013 Category: Respiratory Medicine Source Type: news
NICE issues Appraisal Consultation Document on pemetrexed for the maintenance treatment of non-small-cell lung cancer
Source: NICE
Area: News
NICE has issued new draft guidance not recommending pemetrexed (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin. NICE has already recommended pemetrexed as a first line treatment option for NSCLC and as a maintenance treatment option following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. This appraisal is concerned with the extension to the marketing authorisation for pemetrexed as a maintenance treatment following pemetrexed and cisplatin.
The committee noted th...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news
Chemotherapy Drug Alimta was Sparked by the Wings of a Butterfly
Edward Taylor, the Princeton University chemist whose discovery led to Alimta, will be honored by the National Academy of Sciences. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - January 24, 2013 Category: Environmental Health Authors: TimPovtak Tags: Treatment Lung Cancer Mesothelioma Research Source Type: news
Analysis: Alimta patent seen as Lilly's "wild card"
NEW YORK (Reuters) - Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit. (Source: Reuters: Health)
Source: Reuters: Health - January 4, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
New Treatment Options Featured in NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines
JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN’s panel of oncology experts added pemetrexed (Alimta, Eli Lilly and Company) as an option for second-line therapy for lung cancer. The panel indicated that it has been shown to be equivalent to docetaxel (Taxotere, San... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 28, 2005 Category: Cancer & Oncology Source Type: news
